Biomarin Pharmaceutical Inc. (BMRN) Monday reported third-quarter net loss of $31 million or $0.16 per share, compared to net income of $106 million in the same period last year.
Loss per share for the quarter was $0.16 compared to earnings per share of $0.55 in the same period last year.
Excluding items, Biomarin Pharmaceutical reported adjusted earnings of $22 million or $0.12 per share for the period.
Revenues for the quarter were $776 million, up from $746 million in the same period last year.
Looking forward, Biomarin revised its outlook for the full year 2026. The company now expects revenues of $3.150 to $3.200 billion and adjusted earnings of $3.50 to $3.60 per share.
Previously, the company expected revenues of $3.125 to $3.200 billion and adjusted earnings of $4.40 to $4.55 per share.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.